Therapeutics · Vaccines
Strategy for
Biopharma.
We work with both large and small companies in therapeutics and vaccines. We focus on strategy projects from R&D across the product development lifecycle, to commercial, market access, supply chain, and corporate development. Our projects span the asset/product, portfolio, and firm levels.
FEATURED PERSPECTIVE
- Biopharma ,
- Payers ,
- Institutional
Outcomes Based Arrangements in Biopharma
Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.
"In today’s environment, manufacturers may be less likely to enter into these arrangements"
— Recon analysis
Emerging blood-brain barrier drugs in development
- By Martha Deja, Nicholas Buhay, Marc Herant, and Jason Brauner
- Biopharma
Read more
Outcomes Based Arrangements in Biopharma
- By Lilian Zhang, Tory Wolff, and Jason Brauner
- Biopharma ,
- Payers ,
- Institutional
Read more
Winning on route of administration isn’t enough – lessons from Sotyktu
- By Jason Brauner, Phil Berk, and Lilian Zhang
- Biopharma
Read more
SELECTED CASE STUDIES
How we've helped our biopharma clients
Representative engagements, anonymized. Each pairs deep sector knowledge with rigorous, structured analysis.
- Biopharma
CDMO modality investment strategy
A contract manufacturer needed a full strategy refresh for the decade ahead: markets to serve, capabilities to build, and the cost to get there.
Contract manufacturing service prioritization
- Biopharma, Early Stage
Gene therapy disease assessment
A gene therapy biotech with a novel approach to a fast-moving disease area needed an objective read on the opportunity and on whether it had a credible path to win there.
Crowded market entry decision
- Biopharma, Digital health
Decentralized clinical trial product strategy
A large pharma health-tech arm needed to understand why its decentralized-trial tools weren't landing with users and how to find a defensible point of differentiation.
Clinical research product roadmap